- The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc’s $27.8 billion deal to buy Horizon Therapeutics PLC. Amgen struck a deal last year to buy Horizon to strengthen its rare diseases drugs portfolio. The company has said it hopes to complete the acquisition in the first half of this year. Amgen said on Monday it wasn’t aware of any decision made by the agency. “We will provide any appropriate updates when we have more information,” the company said in a statement. (Articles here and here)
May 16, 2023
M&A | Tea Leaves